Prelude Therapeutics Inc

This management proposal requests a non-binding advisory vote approving the disclosed compensation of the company’s named executive officers (the Say-On-Pay vote). Management is seeking shareholder approval to validate its overall executive compensation program, which the Compensation Committee and an independent consultant designed to reward past performance and create incentives for long-term objectives. The proposal does not approve any single compensation item but rather the overall philosophy and implemented pay practices disclosed in the proxy, including base salary, annual bonus metrics tied to corporate and individual goals, and equity grants intended to align executives with shareholders. The Board and Compensation Committee present this advisory vote to solicit shareholder feedback and to demonstrate accountability, noting that the vote is non-binding but that the Board would consider significant adverse results. Company-specific context includes the Compensation Committee’s engagement of Compensia to benchmark pay and the fact that this is the first Say-On-Pay solicitation since the company previously qualified as an emerging growth company. The Compensation Committee’s disclosure describes target bonus opportunities and severance/change-in-control arrangements, which could be focal points for investor scrutiny. If the vote fails or receives significant negative support, management indicates it will evaluate stockholder concerns and consider changes, although no binding obligation to act exists. Given the company’s recent clinical and operational milestones described as performance objectives for bonuses, management frames pay as linked to achievement of development goals; the Board recommends a vote FOR because it believes the program is effective and aligned with shareholder interests.

This management proposal asks shareholders to indicate, on a non-binding basis, how often the company should hold the advisory Say-On-Pay vote: annually, biennially, or triennially. The Board recommends a one-year frequency, arguing that annual votes give shareholders more frequent and direct input on compensation decisions that are made yearly and offer higher accountability and communication. Management’s rationale references the company’s annual compensation decision cycle and the benefit of more timely shareholder feedback, while noting the vote is advisory and not binding on the Board. In considering governance context, annual Say-On-Pay votes are common for companies seeking regular engagement, but some investors and governance advocates prefer multi-year intervals to reduce administrative costs and focus on longer-term pay outcomes; this tension frames potential investor reaction. The company notes this is the first Say-On-Frequency vote since it was previously an emerging growth company, which may reduce historical shareholder expectations around frequency. The Board also clarifies that it will take the vote result into account but retains discretion to set the ultimate cadence. For sophisticated evaluation, key issues include whether annual votes meaningfully influence compensation decisions or merely increase engagement costs, the company’s stage of development and annual decision-making rhythm, and whether the Board’s flexibility undermines shareholder preferences if the result differs from its recommendation. Overall, the Board’s recommended one-year option aligns with its stated goal of increased accountability and more frequent stockholder input, but investors will weigh that against potential noise from short-term pressures on pay setting.